Abstract: Gastrointestinal tumors exhibit high incidence and mortality rates, with peritoneal metastasis and local recurrence significantly affecting long‑term survival of patients. Clinical studies have demonstrated that hyperthermic intraperitoneal chemotherapy (HIPEC) offers notable advantages in the prevention and treatment of peritoneal metastasis in gastrointestinal tumors, enhancing patient survival while maintaining acceptable safety profiles. However, numerous controversies and challenges persist in the clinical application, management, and operational procedures of HIPEC, hindering its widespread adoption. The authors conduct a systematic evalua-tion of clinical guidelines and expert consensus related to HIPEC, summarizing evidence on its appli-cation and management in gastro-intestinal tumors to provide evidence-based medicine evidences for clinical practice. Future research could focus on tumor type‑specific treatments, the development of multidimensional efficacy predic-tion biomarkers, and the integration of multimodal technologies. By establishing a closed‑loop mana-gement system of "molecular typing‑dynamic monitoring‑precise intervention", HIPEC can be advanced toward individualized, precise, and intelligent development.